Announcement on Obtaining the Approval Letter for the Clinical Trial of Cat Dander Sublingual Film

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.·August 21, 2026·2 pages

✨ AI Summary

Zhejiang I-Mab Biopharma Co., Ltd. announced it has received approval from China's NMPA for the clinical trial of its cat dander sublingual film. This product, intended for allergic rhinitis, complements existing treatments and aims to enhance the company's competitive edge in allergy treatment. The company is preparing for Phase I trials, with outcomes and market prospects remaining uncertain.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300357

Stock Abbreviation: I-Mab Biopharma

Announcement No.: 2026-025

Zhejiang I-Mab Biopharma Co., Ltd.

Announcement on Obtaining the Approval Letter for the Clinical Trial of Cat Dander Sublingual Film

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Recently, Zhejiang I-Mab Biopharma Co., Ltd. (hereinafter referred to as the "Company") obtained the "Drug Clinical Trial Approval Letter" from the government service portal of the National Medical Products Administration. The Company's application for a clinical trial of "Cat Dander Sublingual Film" (hereinafter referred to as "the Product") has been approved. The relevant content is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.